Knight Therapeutics Stock
Price
Target price
€4.94
€4.94
0.000%
-
0.000%
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Knight Therapeutics Stock
The Knight Therapeutics price is unchanged compared to yesterday.
Pros and Cons of Knight Therapeutics in the next few years
Pros
?
M***** P*******
?
S********** s********
?
G***** c******* t* c**********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Knight Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Knight Therapeutics | 0.000% | -5.000% | 6.009% | 34.973% | 32.796% | 45.294% | 38.764% |
| Biomark Diagnostics Inc. | -0.580% | -0.578% | 0.585% | 105.988% | 24.638% | 85.946% | 42.149% |
| MicroPlanet Technology Corp | 6.350% | 4.688% | 4.688% | 2.290% | -11.842% | -16.250% | -16.250% |
| Avricore Health Inc. | - | -12.281% | -28.571% | -13.793% | 8.696% | -86.034% | -77.273% |
News
Integra LifeSciences Says Transformation Is Working as SurgiMend Relaunch Nears
Integra LifeSciences (NASDAQ:IART) is keeping its core strategy intact following a leadership change that returned Stuart to the roles of chairman and chief
Rapid Micro Biosystems Q1 Earnings Call Highlights
Rapid Micro Biosystems (NASDAQ:RPID) reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook, citing momentum in system placements, consumables and recurring revenue, while
Cannae Q1 Earnings Call Highlights
Cannae (NYSE:CNNE) said it returned the bulk of its first-quarter capital allocation to shareholders while continuing to evaluate sales of non-core holdings and emphasizing growth in its